#USA #San Francisco #Gene Editing #CellFE #Syenex

CellFE and Syenex Revolutionize Gene Editing Workflows

In a remarkable development for cell therapy engineering, CellFE®, a front-runner in non-viral gene editing technology, has teamed up with Syenex, a pioneer in enveloped delivery vectors. This collaboration promises to bring forth a novel hybrid workflow aimed at integrating both non-viral and viral approaches to streamline the process of editing complex cells, a significant advancement for biotech and pharmaceutical sectors.

The official announcement of this collaboration is set to coincide with the prestigious J.P. Morgan Healthcare Conference taking place in San Francisco from January 13-16, 2025. This annual event is recognized as a gathering hub for industry leaders, investors, and innovative thinkers from across the globe, making it the perfect platform to unveil significant advancements in medical technology.

The Significance of Integration

The new hybrid workflow is crafted specifically to meet the growing market demand for a solution that effectively merges non-viral knockout techniques with viral knockin capabilities. The aim is to foster a development process that not only maintains but enhances the viability and functionality of engineered cells, ensuring they undergo minimal stress during modification.

Dr. Alla Zamarayeva, CEO of CellFE, emphasized the necessity of such advancements by stating, "The market has been anticipating a solution that seamlessly integrates non-viral knockout with viral knockin capabilities. This partnership fulfills that critical need."

Echoing this sentiment, Jay Rosanelli, CEO of Syenex, highlighted the essence of collaborative science in advancing the medical field. He stated, "This joint effort showcases how collaboration can expedite the creation of transformative medicines for patients worldwide. We are excited about the potential of this hybrid workflow to revolutionize the manufacturing processes for genetic medications."

Addressing Current Challenges

As the field of cell therapy rapidly evolves, providers focusing on both allogeneic and autologous cell therapies are encountering increased pressure to optimize their manufacturing protocols. Historically, delivery methods such as viral transduction and electroporation have posed challenges. They often jeopardize cell integrity and lengthen recovery times, especially when dealing with intricate, sequential gene edits.

The newly proposed hybrid workflow promises to address these issues by ensuring safe, effective, and efficient delivery of gene-editing tools to the target patient cells. The core objective is to sustain high cellular functionality during the editing process, which is crucial for any subsequent therapeutic application.

Opportunities for Engagement

As part of their participation in the upcoming J.P. Morgan Healthcare Conference, both CellFE and Syenex are eager to engage with potential partners and stakeholders within the industry. This engagement signifies a pivotal moment for scientists and innovators aiming to address the complexities of cell therapy development.

Details about how to partner with CellFE and Syenex during the conference can be found through their respective websites. Attendees will have opportunities to engage with company representatives at various events throughout the conference week.

About CellFE

CellFE is a microfluidics company on a mission to revolutionize the development and manufacturing processes of life-saving cell therapies. They focus on making cellular treatments more accessible by tackling the primary challenges of high costs and protracted timelines. Specializing in T-Cell, HSC, and iPSC-based therapies, CellFE employs cutting-edge gene delivery technologies to address pertinent bottlenecks in the realm of cell therapy manufacturing.

For more information about CellFE, visit www.cellfebiotech.com.

About Syenex

Syenex is at the forefront of bioengineering innovation, crafting scalable gene delivery vectors designed to empower developers in the field of cell and gene therapy. This organization aims to provide widespread access to their expanding suite of bioengineering tools while collaborating with partners to drive breakthroughs in medical technology.

Explore more about Syenex at www.syenex.com.

This unprecedented collaboration marks a significant step towards a more integrated approach in gene editing technologies, promising a future where cell therapies can be developed more effectively and efficiently, ultimately benefiting patients around the world.